CoChat

Blocking Interleukin‐1 in Rheumatic Diseases: Its Initial Disappointments and Recent Successes in the Treatment of Autoinflammatory Diseases

Open access
Goldbach‐Mansky, Raphaela · 2009 · Annals of the New York Academy of Sciences
Cited by 96

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

The role of the potent proinflammatory cytokine IL‐1 in disease could clinically be investigated with the development of the IL‐1 blocking agent anakinra (Kineret®), a recombinant IL‐1 receptor antagonist. It was first tested in patients with sepsis without much benefit but was later FDA approved for the treatment of patients with rheumatoid arthritis. More recently IL‐1 blocking therapies are used successfully to treat a new group of immune‐mediated inflammatory conditions, autoinflammatory diseases. These conditions include rare hereditary fever syndromes and pediatric and adult conditions of Still's disease. Recently the FDA approved two additional longer acting IL‐1 blocking agents, for the treatment of cryopyrin‐associated periodic syndromes (CAPS), an IL‐1 dependent autoinflammatory syndrome. The study of autoinflammatory diseases revealed mechanisms of IL‐1 mediated organ damage and provided concepts to a better understanding of the pathogenesis of more common diseases such as gout and Type 2 diabetes which show initial promising results with IL‐1 blocking therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1749-6632.2009.05159.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 96

Metadata

Authors
Goldbach‐Mansky, R.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
2009-12
Volume
1182
Issue
1
Pages
111-123
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W2158250741
Cited by
96
References
8
FWCI
3.96
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blocking Interleukin‐1 in Rheumatic Diseases: Its Initial Disappointments and Recent Successes in the Treatment of Autoinflammatory Diseases. https://app.cochat.ai/papers/10.1111/j.1749-6632.2009.05159.x
The paper
Goldbach‐Mansky, R. (2009). Blocking Interleukin‐1 in Rheumatic Diseases: Its Initial Disappointments and Recent Successes in the Treatment of Autoinflammatory Diseases. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2009.05159.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.